Advertisement


Sibylle Loibl, MD, PhD, on Metastatic Breast Cancer: Expert Perspective on CDK4 Inhibitors

2017 ESMO Congress

Advertisement

Sibylle Loibl, MD, PhD, of the German Breast Group, summarizes a session she chaired in which the rationale to target CDK4, data on efficacy of the inhibitors, and triple combination therapy with PI3K were discussed.



Related Videos

Breast Cancer

Marleen Kok, MD, PhD, on Triple-Negative Breast Cancer: Results From the TONIC Trial

Marleen Kok, MD, PhD, of The Netherlands Cancer Institute, discusses findings from an adaptive phase II noncomparative trial of nivolumab after induction treatment in triple-negati...

Head and Neck Cancer

Robert I. Haddad, MD, on Head and Neck Cancer: Results of the CheckMate 141 Trial

Robert I. Haddad, MD, of Dana-Farber Cancer Institute, discusses phase III study results on treatment beyond disease progression with nivolumab in patients with recurrent or metast...

Gynecologic Cancers

Domenica Lorusso, MD, PhD, on Cervical Cancer: Results From a Trial on Treatment Regimens

Domenica Lorusso, MD, PhD, of the National Cancer Institute of Milan, discusses neoadjuvant chemotherapy followed by surgery vs concurrent cisplatin and radiation therapy in patien...

Gynecologic Cancers

Simone Koole, MD, on Ovarian Cancer: Results of the OVHIPEC Trial

Simone Koole, MD (and a PhD candidate), of the Netherlands Cancer Institute, discusses phase III findings on health-related quality of life after hyperthermic intraperitoneal chemo...

Pancreatic Cancer

David A. Tuveson, MD, PhD, on Progress in Pancreatic Cancer: Expert Perspective

David A. Tuveson, MD, PhD, of Cold Spring Harbor Laboratory, discusses the most lethal of cancers. Although treatments are improving, the challenges are great, including early dete...

Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.